Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Nicotinic acetylcholine receptor alpha subunit

5

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

3

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1990

3

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Ascariasis

3

Dukes' Stage C colon cancer

3

Steroid-sensitive idiopathic nephrotic syndrome

3

Helminthiasis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

5

Palliative

3

Preventing

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

American Cyanamid

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

NCI_THESAURUS

5

PUBCHEM

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTHELMINTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTINEMATODAL AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Imidazothiazole derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LEVAMISOLE

2880D3468G

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1990

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Nicotinic acetylcholine receptor alpha subunit

Alkaline phosphatase, tissue-nonspecific isozyme

Conditions:

Dukes' Stage C colon cancer

Steroid-sensitive idiopathic nephrotic syndrome

Levamisole (the trade name Ergamisol), an anthelminthic drug with immunological properties. It also has antitumor activity when administered with 5-fluorouracil in patients with Duke's C colorectal carcinoma; however, this use was discontinued. The m...

echanism of the antitumor effect is unknown but has been postulated to be related to levamisole's immunomodulatory properties. Levamisole can stimulate antibody formation to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis, chemotaxis and increases motility, adherence, and chemotaxis. Levamisole inhibits alkaline phosphatase and possesses cholinergic activity. The mechanism of action of levamisole as an antiparasitic agent, for example, to treat ascariasis, relates to its agonistic activity to L-subtype nicotinic acetylcholine receptors in nematode muscles. In addition, levamisole was studied for preventing relapses of the steroid-sensitive idiopathic nephrotic syndrome (SSINS). It was shown, that alone or in combination with steroids, the drug can prolong the time to relapse and prevented recurrence during one year of treatment. However, these studies also were also discontinued.

BUTAMISOLE

XVB7982801

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Nicotinic acetylcholine receptor alpha subunit

Conditions:

Butamisole is an injectable imidazothiazoles anthelmintic. In dogs it is used for the treatment of infections with whipworms (Trichuris vulpis ), and the hookworm (Ancylostoma caninum ). Nicotinic acetylcholine receptor agonist. Acts as agonist at ni...

cotinic Ach receptor of nematode à ganglionic stimulation causes sustained muscle contraction initially followed by depolarising neuro muscular blockade which in turn leads to spastic paralysis.

LEVAMISOLE PHOSPHATE

FIG89N8AZY

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1990

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Nicotinic acetylcholine receptor alpha subunit

Alkaline phosphatase, tissue-nonspecific isozyme

Conditions:

Dukes' Stage C colon cancer

Steroid-sensitive idiopathic nephrotic syndrome

Levamisole (the trade name Ergamisol), an anthelminthic drug with immunological properties. It also has antitumor activity when administered with 5-fluorouracil in patients with Duke's C colorectal carcinoma; however, this use was discontinued. The m...

echanism of the antitumor effect is unknown but has been postulated to be related to levamisole's immunomodulatory properties. Levamisole can stimulate antibody formation to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis, chemotaxis and increases motility, adherence, and chemotaxis. Levamisole inhibits alkaline phosphatase and possesses cholinergic activity. The mechanism of action of levamisole as an antiparasitic agent, for example, to treat ascariasis, relates to its agonistic activity to L-subtype nicotinic acetylcholine receptors in nematode muscles. In addition, levamisole was studied for preventing relapses of the steroid-sensitive idiopathic nephrotic syndrome (SSINS). It was shown, that alone or in combination with steroids, the drug can prolong the time to relapse and prevented recurrence during one year of treatment. However, these studies also were also discontinued.

LEVAMISOLE HYDROCHLORIDE

DL9055K809

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1990

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Nicotinic acetylcholine receptor alpha subunit

Alkaline phosphatase, tissue-nonspecific isozyme

Conditions:

Dukes' Stage C colon cancer

Steroid-sensitive idiopathic nephrotic syndrome

Levamisole (the trade name Ergamisol), an anthelminthic drug with immunological properties. It also has antitumor activity when administered with 5-fluorouracil in patients with Duke's C colorectal carcinoma; however, this use was discontinued. The m...

echanism of the antitumor effect is unknown but has been postulated to be related to levamisole's immunomodulatory properties. Levamisole can stimulate antibody formation to various antigens, enhance T-cell responses by stimulating T-cell activation and proliferation, potentiate monocyte and macrophage functions including phagocytosis, chemotaxis and increases motility, adherence, and chemotaxis. Levamisole inhibits alkaline phosphatase and possesses cholinergic activity. The mechanism of action of levamisole as an antiparasitic agent, for example, to treat ascariasis, relates to its agonistic activity to L-subtype nicotinic acetylcholine receptors in nematode muscles. In addition, levamisole was studied for preventing relapses of the steroid-sensitive idiopathic nephrotic syndrome (SSINS). It was shown, that alone or in combination with steroids, the drug can prolong the time to relapse and prevented recurrence during one year of treatment. However, these studies also were also discontinued.

BUTAMISOLE HYDROCHLORIDE

QGM18599H5

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Nicotinic acetylcholine receptor alpha subunit

Conditions:

Butamisole is an injectable imidazothiazoles anthelmintic. In dogs it is used for the treatment of infections with whipworms (Trichuris vulpis ), and the hookworm (Ancylostoma caninum ). Nicotinic acetylcholine receptor agonist. Acts as agonist at ni...

cotinic Ach receptor of nematode à ganglionic stimulation causes sustained muscle contraction initially followed by depolarising neuro muscular blockade which in turn leads to spastic paralysis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1